NovelStem International Corp. (NSTM) stock: key figures, P/E, revenue and dividend

Consumer Discretionary · United States

Price
0.01 USD
Market cap
493,324.55 USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-111.12 %
Return on assets (ROA)
15,075.90 %

NovelStem International Corp. financials

Fiscal year20242025
Operating income-927,922.00 USD-238,755.00 USD
EBIT-2.81 m USD2.42 m USD
Net income-3.23 m USD2.38 m USD
Diluted EPS – continuing operations-0.07 USD0.05 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About NovelStem International Corp.

NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.